Company Profile

BTG plc is medical device development and healthcare service provider. It provides Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care and licensing business. It operates through three segments: Interventional Medicine, Pharmaceuticals and Licensing. The Interventional Medicine segment includes oncology, vascular and pulmonology. The segment's products include Beads, TheraSphere, EkoSonic, Varithena and PneumRx Coils for use in the treatment of liver tumors, blood clots, varicose veins and advanced emphysema. The Pharmaceuticals segment includes CroFab, DigiFab, Voraxaze and Vistogard products for use in the treatment of crotalid envenomation, digoxin toxicity, high-dose methotrexate toxicity and 5-fluorouracil toxicity. The Licensing segment includes Zytiga, Two-Part Hip Cup and Lemtrada products for use in the treatment of advanced prostate cancer, hip replacement and multiple sclerosis.

Employees

Sector

Pharmaceuticals

More about the company

19-07-29	MRV Engenharia e Participacoes : Brazil's Banco Inter lures Japan's Softbank Group in share offering -source	RE
19-07-29	Fintechs at the gate: online brokers target affluent Brazilians	RE
19-05-15	Boeing : Brazil's Embraer posts quarterly loss due to fewer plane deliveries	RE
19-05-14	Ashtead : What's at stake for Europe Inc in a trade spat with Washington	RE
18-11-20	FTSE : Brexit woes push FTSE to three-week lows; investors dump banks, oil	RE
18-11-20	GLOBAL MARKETS LIVE: Boston Scientific, SocGen, Nissan, Apple…
18-11-20	Boston Scientific : builds medical tech with $4.2 billion BTG deal	RE
18-11-13	FTSE : Stronger pounds weighs on FTSE, offsetting Vodafone uplift	RE
18-11-13	Brexit, trade progress drive European stocks up after tech rout	RE
18-10-04	European shares suffer biggest fall in a month after bond yield surge	RE
18-10-04	BTG : Pharma upgrades sales guidance after strong first half	RE
18-09-07	BTG : British healthcare firm BTG buys Irish vascular device maker	RE
18-01-18	BTG : U.S. court invalidates Johnson & Johnson cancer drug patent, hitting UK's BTG	RE

19-08-19	BTG : Form 8.3 - BTG Plc	PU
19-08-19	BTG : Form 8.5 (EPT/RI) - BTG plc	PU
19-08-19	BTG : Boston Scientific Closes Acquisition of BTG plc.	PR
19-08-19	BTG : Form 8.5 (EPT/NON-RI) - BTG PLC	PU
19-08-19	BTG : Form 8.5 (EPT/RI) BTG plc	PU

19-08-28	Les Bourses asiatiques hésitent, suspendues aux tensions commerciales
19-05-14	Fresenius Medical Care : Les valeurs européennes les plus exposées à la guerre commerciale
18-11-30	Avis d'analystes du jour : Valeo, Faurecia, Arkema, Renault, Neoen, Safran, ING...
18-11-30	Le CAC40 sur les 5 000 points avant le G20
18-11-20	USA-Les valeurs à suivre à Wall Street (actualisé)

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BTG	-.--%	+0.12%	-	-	3.99B
ELI LILLY AND COMPANY	-0.04%	-1.40%	+57.16%	+108.15%	1,034B
JOHNSON & JOHNSON	+1.17%	+4.76%	+56.42%	+73.50%	671B
ABBVIE INC.	-0.58%	+0.80%	+22.82%	+75.58%	460B
ROCHE HOLDING AG	+2.09%	-2.06%	+32.28%	+37.41%	353B
NOVARTIS AG	0.00%	+5.36%	+27.40%	+46.97%	309B
ASTRAZENECA PLC	+1.42%	+0.26%	-0.52%	+13.51%	255B
AMGEN INC.	+0.29%	+1.63%	+56.46%	+73.00%	240B
NOVO NORDISK A/S	-0.03%	+2.13%	-17.30%	-53.65%	207B
GILEAD SCIENCES, INC.	+1.08%	+1.59%	+33.83%	+97.29%	188B
Average	+0.48%	+1.27%	+29.84%	+52.42%	412.97B
Weighted average by Cap.	+0.34%	+1.04%	+38.60%	+67.71%

BTG Stock

Stocks

GB0001001592

Pharmaceuticals

Latest news : BTG

Press Releases : BTG

News in other languages : BTG

Managers and Directors : BTG

Other Pharmaceuticals

Company Profile